UPSTREAM BIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
UPSTREAM BIO, INC. (UPB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.35M, a 67.65% increase year-over-year.
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.65M, a 76.36% increase year-over-year.
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.59M, a 39.24% increase year-over-year.
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.60M, a 83.92% increase year-over-year.
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.33M, a 72.09% increase from fiscal 2024.
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $6.00M, a 80.57% increase from fiscal 2023.
- UPSTREAM BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $3.33M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.35M 10-Q · filed 2026-08-11 | $9.00M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $4.65M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $10.33M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $2.59M 10-Q · filed 2025-11-05 | $5.19M derived: sum of 2 quarters · filed 2026-08-11 | $7.83M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $2.60M 10-Q · filed 2026-08-11 | $5.23M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $2.63M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $6.00M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $1.86M 10-Q · filed 2025-11-05 | $3.27M derived: sum of 2 quarters · filed 2025-11-05 | $3.92M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $1.41M 10-Q · filed 2025-11-05 | $2.06M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $643.00K 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $3.33M 10-K · filed 2025-03-12 | |||
| 2023-09-30 | $683.00K 10-Q · filed 2024-11-07 | $1.31M derived: sum of 2 quarters · filed 2024-11-07 | $2.61M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $627.00K 10-Q · filed 2024-11-07 | $1.93M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $1.30M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |